


CLAIMS


1. A prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain which comprises as an active ingredient a compound having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt thereof.
2. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 1, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a xanthine derivative.
3. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 1, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a xanthine derivative represented by formula (I):



[wherein R¹, R² and R³ are the same or different, each representing a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl;

R⁴ represents cycloalkyl, -(CH₂)_n-R⁵ (in which R⁵ represents


substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4) or formula (II):



(wherein Y^1 and Y^2 are the same or different, each representing a hydrogen atom, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group); and X^1 and X^2 are the same or different, each representing an oxygen atom or a sulfur atom].

4. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 3, wherein X^1 and X^2 each is an oxygen atom.


5. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 3 or 4, wherein R^4 is a formula (II):



(wherein Y^1 , Y^2 and Z each has the same meanings as mentioned above).


6. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 5, wherein Y^1 and Y^2 each is a hydrogen atom.

7. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 5 or 6, wherein Z is substituted or unsubstituted aryl or a group represented by formula (III):




(wherein R^6 represents a hydrogen atom, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3).

8. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 5 or 6, wherein Z is a group represented by formula (IV):



(wherein at least one of R^7 , R^8 and R^9 represents lower alkyl or lower alkoxy and the remaining groups represent a hydrogen atom; R^{10} represents a hydrogen atom or lower alkyl)

or formula (III):




(wherein R^6 and m each has the same meanings as mentioned above).

9. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in any of Claims 3 to 8, wherein R^1 and R^2 each is ethyl.

10. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in any of Claims 3 to 9, wherein R^3 is methyl.

11. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 1, wherein the compound having an adenosine A_{2A} receptor antagonistic action is a compound represented by formula (1):



12. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in any of Claims 1 to 11, wherein the disease accompanied by chronic

musculoskeletal pain is fibromyalgia syndrome.

13. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in any of Claims 1 to 12, wherein the disease accompanied by chronic musculoskeletal pain is a disease relating to fibromyalgia syndrome.

14. The prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain as claimed in Claim 13, wherein the disease relating to fibromyalgia syndrome is one selected from fibrositis, chronic fatigue syndrome, myofascial pain syndrome, diffuse myofascial pain syndrome, generalized fibrinitis, soft tissue rheumatism, non-articular rheumatism, chronic rheumatoid arthritis, primary fibromyalgia syndrome, concomitant fibromyalgia syndrome, idiopathic muscle pain syndrome, chronic widespread musculoskeletal pain, low back pain, Lyme disease accompanied by fibromyalgia syndrome, generalized tendomyopathy, and temporomansibular joint disorder.

15. A method of preventing and/or treating diseases accompanied by chronic musculoskeletal pain which comprises administering an effective amount of a compound having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt thereof.

16. Use of a compound having an adenosine A_{2A} receptor antagonistic action or a pharmaceutically acceptable salt

thereof for the manufacture of a prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain.